Ion Pacific acts as Sole Financial Adviser in Taiwan Biotech Company’s US$106 million convertible bond issue.
Taiwan cancer drugs developer seeks Hong Kong bond issue ahead of IPO after delisting from Taipei JHL Biotech, a Taiwan developer of cheaper alternatives to patent-protected biological drugs, has raised US$106 million from a convertible bond issue, ahead of its planned Hong Kong initial public offering (IPO) aiming to raise some US$250 million. Attracted by […]
